产免疫调节活性多糖海洋放线菌的筛选  

Screening of marine actinomycetes producing polysaccharides with immunomodulating activity

作　　者：苏文金[1,2] 黄益丽[1] 黄耀坚[1] 郑忠辉[1] 宋思扬[1] 陈晋安[1] 

机构地区：[1]厦门大学细胞生物学和肿瘤细胞工程教育部重点实验室和生命科学学院 [2]集美大学水产生物技术研究所,福建厦门361021

出　　处：《海洋学报》2001年第6期114-119,共6页

基　　金：国家海洋"863"计划资助项目 ( 819- 0 5 - 0 8) ;福建省科委重点资助项目 ( 98-Z - 7)

摘　　要：用硫酸苯酚法和实验动物模型检测分离于厦门海区潮间带的 996株海洋放线菌胞外多糖产量和体内外免疫增强活性 .结果表明 ,3 3%的海洋放线菌粗多糖产量大于 3g/dm3;在粗多糖产量高的海洋放线菌中有 3株菌株的胞外多糖在体内外均具有较好的免疫增强活性 ,其中链霉菌 (Streptomycessp .) 2 30 5菌株的胞外多糖具有较高的非特异性、细胞及体液免疫增强活性 .研究结果表明海洋放线菌胞外多糖是免疫调节剂开发的重要资源 .The purpose of this work is to investigate the production of the extracellular polysaccharides(EPS) with immunomodulating activity from marine actinomycetes. 996 strains of marine actinomycetes are isolated from intertidal zone of Xiamen Island, and 3.3% of them yield EPS more than 3 g/dm 3 when determined by method of phenol-sulfuric acid. Among the strains with high yield of EPS, there are 3 strains those produe the EPS having immunomodulating activity in vitro by promoting the proliferation and accumulation of interleukin 2 (IL-2) of lymphocytes of mouse spleen and in vivo in the animal model. The EPS produced by Strain 2305, Streptomyces sp., is the most promising candidate to develop into immunomodulator in view of its obvious effects on the non-specific, cellular and humoral immunity. The results show that the EPS from marine actinomycetes can be an important resource for the development of immunomodulators.

关 键 词：海洋放线菌 胞外多糖 免疫调节剂 海洋药物 硫酸苯酚法 潮间带 链霉菌 

分 类 号：Q939.132[生物学—微生物学] R282.77[医药卫生—中药学]